Roche will halt development of ocrelizumab for rheumatoid arthritis

Roche Holding plans to stop developing ocrelizumab as a treatment for rheumatoid arthritis because the drug's risk profile proved to be unfavorable when compared with existing treatments in an effectiveness and safety review. Roche said midstage trials of the drug, co-developed by Biogen Idec, for relapsing remitting multiple sclerosis are ongoing.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Operating Officer
Health Plan of San Joaquin
French Camp , CA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Children's Health Plan
Houston, TX
Chief Information Officer
Meridian Health Plan
Detroit, MI
Actuary
NTA Life
Addison, TX
Vice President - Government Products
Health Alliance Plan
Detroit, MI